Two very public conversations have caused this perceived negativity around stem cells and they are important to fully understand. Firstly, and recently, the industry has been plagued by a rush to market for therapies that have not been tested, or therapies not actually rooted in science. Like any new innovation, the hype and anticipation has caused a market rush from many players who are not necessarily rooted in sound medical science. Acorn was born out of fundamental molecular and cell science and we are committed to help facilitate visibility to the therapies that are based in real science that can make a difference in your life. The second area that has caused negativity around stem cell research started nearly 20 years ago as scientists first explored the use of embryonic stem cells for research. Obviously harvesting stem cells from unborn embryos was fraught with ethical issues and drove significant controversy.
The remarkable discovery of iPSCs in 2012 has thankfully put to rest any need to harvest stem cells from sources that compromise ethics. Acorn developed patented technologies that have been able to bring the value of cells to everyone in an accessible and affordable way. While we are many years past the initial controversial use of embryos for stem cells, the negativity still persists. Taking the time to educate yourself on stem cells and the current areas of research will allow you to fully understand and take advantage of what real science can deliver to the promise of cell and gene therapy.
